SCHEMBL17832183

SCHEMBL17832183

CC(C)(Br)CC(C)(C)Oc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA4 P22748 1/20 0.37
PPARG P37231 4/20 0.37
PPARA Q07869 2/20 0.37
RIPK1 Q13546 1/20 0.36
SLC6A2 P23975 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
LTA4H P09960 2/20 0.35
TSHR P16473 1/20 0.35
KCNA3 P22001 1/20 0.34
CYP2D6 P10635 2/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
MAPK1 P28482 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.32
HTR1D P28221 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15202532 0.85 SLC6A2 (0.39) CA4PPARGPPARARIPK1SLC6A2
SCHEMBL899654 0.84 RIPK1 (0.41) CA4PPARGPPARARIPK1SLC6A2
SCHEMBL23899116 0.81 ELANE (0.54) PPARGPPARAMAPTALDH1A1LMNA
SCHEMBL17772105 0.81 PPARG (0.37) CA4PPARGPPARARIPK1SLC6A2
SCHEMBL7018083 0.80 CA4 (0.39) CA4PPARGPPARARIPK1SLC6A2
SCHEMBL294173 0.80 CA4 (0.39) CA4PPARGPPARARIPK1SLC6A2
Ethylene Glycol SCHEMBL5936849 0.78 ALDH1A1 (0.41) CA4PPARGPPARARIPK1LTA4H
SCHEMBL14303651 0.78 PPARA (0.39) PPARGPPARA
SCHEMBL183720 0.77 LTA4H (0.40) CA4PPARGPPARARIPK1SLC6A2
SCHEMBL11613159 0.77 CA4 (0.36) CA4PPARGPPARARIPK1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9944628-B2 Inhibitors of cellular necrosis and related methods PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-04-17 US disclosed
US-9499521-B2 Inhibitors of cellular necrosis and related methods PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-11-22 US disclosed
US-20160304498-A1 INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-20 US disclosed
US-20160168128-A1 INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168128-A1 INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS LITAF, TNF, MMP8 CA4 929/4885PPARG 2698/4885PPARA 2535/4885
US-20160304498-A1 INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS LITAF, TNF, MMP8 CA4 929/4885PPARG 2698/4885PPARA 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.